News
About the PCSK9 Education and Research Forum
PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
Download Now: New Slide Deck Programme
Slide decks focusing on key results and expert analysis from FOURIER and ODYSSEY OUTCOMES – two landmark trials in PCSK9 inhibition.
Find out more »
Hot Topics
News from the 10th Expert Meeting of the Editorial Board of PCSK9 Education and Research Forum
Treatment Guidelines: Now and the Future
Professor Henry Ginsberg (University of Columbia, New York, USA): The 2018 AHA/ACC Treatment guidelines: Key learnings
Watch Webcast
Professor Børge Nordestgaard (University of Copenhagen, Denmark): Lipoprotein(a): a therapeutic target in guidelines?
Watch Webcast
From the Editors
Surfing the PCSK9 wave of discovery
Novel approaches to PCSK9 inhibition, including inclisiran and LIB003, have made the news. Prof Derick Raal (University of Witwatersrand, Johannesburg, South Africa) gives his perspective on the newest ‘PCSK9 kids on the block’ amidst the wave of PCSK9 discovery.
Read the report
Latest Views
Meet our Editorial Board
View all our Editorial Board
Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie
Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research
Dr Michel FarnierClinician based at Point Medical, Dijon, France
Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit
Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology
